November 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase

Pedro Perez/LinkedIn

Jan 22, 2026, 10:38

Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase

Pedro Perez, Vascular Consultant – PERT and VTE Program Builder at Argon Medical Devices, Inc., shared on LinkedIn:

”The VTE market is clearly entering its next phase

With Penumbra joining Boston Scientific and Inari becoming part of Stryker, the two category-defining innovators are now backed by global strategics with massive scale, capital, and contracting power.

These companies earned their leadership through time in market, differentiated technology, clinical evidence, and deep physician trust — advantages that are hard to replicate.

What does this mean for the rest of the field?

The VTE space is increasingly crowded, but the available market share is limited.

New and emerging competitors are fighting uphill for protocol inclusion, value analysis approval, workflow adoption, and mindshare in labs already standardized around established platforms.

We’re shifting from an innovation-first era to a scale, execution, and economic-value era.

Going forward, success won’t come from “me too” devices — it will come from clear clinical differentiation, operational simplicity, and undeniable total cost impact.

Consolidation isn’t slowing competition.

It’s raising the bar.”

Stay updated with Hemostasis Today.